Clinical Trials
21 trialsNCT00720304 2024-08-22
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05832593 2023-04-27
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.
Assiut University
Unknown
NCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT01020097 2020-04-28
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT00498953 2018-07-09
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00646659 2018-07-09
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00601913 2018-07-05
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Completed
NCT00757549 2017-10-31
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01192750 2017-05-17
Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab
Eastern Cooperative Oncology Group
Completed
NCT01194635 2017-05-17
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
Eastern Cooperative Oncology Group
Completed
NCT01466244 2017-05-17
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
Eastern Cooperative Oncology Group
Completed
NCT01487733 2017-05-17
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301
Eastern Cooperative Oncology Group
Completed
NCT03026361 2017-01-20
Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity
University of Zagreb
Completed
NCT00012168 2016-03-11
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
NYU Langone Health
Phase NA Completed
NCT00900302 2016-02-10
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
OHSU Knight Cancer Institute
Completed
NCT00049140 2014-07-25
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
Duke University
Phase 2 Completed
NCT00415298 2014-01-10
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT00898664 2013-04-02
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Completed
NCT00899340 2013-04-02
Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx
Vanderbilt-Ingram Cancer Center
Completed
NCT00357617 2010-12-24
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Unknown